Keros Therapeutics (KROS)
NASDAQ:KROS
US Market
Holding KROS?
Track your performance easily

Keros Therapeutics (KROS) Ownership - Who Owns Keros Therapeutics?

230 Followers

Keros Therapeutics (KROS) Ownership Overview

8.69%21.10%37.52%10.40%22.29%
37.52% Other Institutional Investors
10.40% ETFs
22.29% Public Companies and
Individual Investors
The ownership structure of Keros Therapeutics (KROS) stock is a mix of institutional, retail, and individual investors. Approximately 69.02% of the company’s stock is owned by Institutional Investors, 8.69% is owned by Insiders, and 22.29% is owned by Public Companies and Individual Investors.
The ownership structure of {name} ({ticker}) stock is a mix of institutional, retail, and individual investors. {displayInstitutionalData, select, display {Approximately {institutionalPercentage} of the company’s stock is owned by Institutional Investors} other {}}{displayInsiderText, select, display {, {insidersPercentage} is owned by Insiders} other {}}{displayInvestorsText, select, display {, and {retailInvestorsPercentage} is owned by Public Companies and Individual Investors.} other {}}

Recent Insider Trading Activity

Date
Name
Activity
Value
Aug 15, 2024
Carl Gordon
Director
xxxxxxxxxxxxx
$11002500
Aug 15, 2024
xxxxxxxxxxxxx
$11002500

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Sep 30, 2024
xxxxxxxxxxxxx
$927390
Sep 30, 2024
xxxxxxxxxxxxx
$35456116

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
1,704,043Institution4.21%102,838,995
1,462,864Institution3.61%88,283,842
1,382,468Institution3.41%83,431,944
1,226,412Insider3.03%74,013,964
1,226,412Insider3.03%74,013,964
1,000,983Institution2.47%60,409,324
949,129Institution2.34%57,279,935
881,001Institution2.17%53,168,410
775,845Institution1.92%46,822,246
649,200Institution1.60%39,179,220

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
1,382,468Institution3.41%83,431,944
1,000,983Institution2.47%60,409,324
949,129Institution2.34%57,279,935
881,001Institution2.17%53,168,410
649,200Institution1.60%39,179,220
602,761Institution1.49%36,376,626
499,208Institution1.23%30,127,203
430,600Institution1.06%25,986,710
326,894Institution0.81%19,728,053
310,310Institution0.77%18,727,209

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
960,390Institution2.37%55,769,847
832,793Institution2.06%50,259,058
478,338Institution1.18%30,168,778
482,147Institution1.19%27,998,276
265,761Institution0.66%16,038,676
205,657Institution0.51%12,411,400
155,891Institution0.38%9,832,045
135,250Institution0.33%7,853,968
96,210Institution0.24%5,586,915
44,240Institution0.11%2,790,217

FAQ

Who Owns Keros Therapeutics (KROS)?
According to the latest TipRanks data, approximately 37.52% of the company's stock is held by institutional investors, 8.69% is held by insiders, and 22.29% is held by retail investors.
    What percentage of Keros Therapeutics (KROS) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 37.52% of Keros Therapeutics (KROS) stock is held by institutional investors.
      What percentage of Keros Therapeutics (KROS) stock is held by retail investors?
      According to the latest TipRanks data, approximately 22.29% of Keros Therapeutics (KROS) stock is held by retail investors.
        Who owns the most shares of Keros Therapeutics (KROS)?
        Vanguard owns the most shares of Keros Therapeutics (KROS).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis